251 related articles for article (PubMed ID: 12678768)
1. DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.
Holden JA
Curr Med Chem Anticancer Agents; 2001 May; 1(1):1-25. PubMed ID: 12678768
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase as target for antibacterial and anticancer drug discovery.
Kathiravan MK; Khilare MM; Nikoomanesh K; Chothe AS; Jain KS
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):419-35. PubMed ID: 22380774
[TBL] [Abstract][Full Text] [Related]
4. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
Holden JA
Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
[TBL] [Abstract][Full Text] [Related]
5. Development of DNA topoisomerase-related therapeutics: a short perspective of new challenges.
Capranico G; Zagotto G; Palumbo M
Curr Med Chem Anticancer Agents; 2004 Jul; 4(4):335-45. PubMed ID: 15281906
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerases as targets for anticancer drugs.
Topcu Z
J Clin Pharm Ther; 2001 Dec; 26(6):405-16. PubMed ID: 11722677
[TBL] [Abstract][Full Text] [Related]
7. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
Withoff S; De Jong S; De Vries EG; Mulder NH
Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Pommier Y; Leo E; Zhang H; Marchand C
Chem Biol; 2010 May; 17(5):421-33. PubMed ID: 20534341
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.
You F; Gao C
Curr Top Med Chem; 2019; 19(9):713-729. PubMed ID: 30931860
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents.
Kathiravan MK; Kale AN; Nilewar S
Mini Rev Med Chem; 2016; 16(15):1219-1229. PubMed ID: 27549098
[TBL] [Abstract][Full Text] [Related]
11. From DNA damage to G2 arrest: the many roles of topoisomerase II.
Larsen AK; Escargueil AE; Skladanowski A
Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
[TBL] [Abstract][Full Text] [Related]
12. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
14. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.
Fortune JM; Osheroff N
Prog Nucleic Acid Res Mol Biol; 2000; 64():221-53. PubMed ID: 10697411
[TBL] [Abstract][Full Text] [Related]
16. An overview of topoisomerase I-targeting agents.
Arbuck SG; Takimoto CH
Semin Hematol; 1998 Jul; 35(3 Suppl 4):3-12. PubMed ID: 9779876
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Tavian D; Silvestrini A
Curr Med Chem; 2017; 24(15):1607-1626. PubMed ID: 27978799
[TBL] [Abstract][Full Text] [Related]
18. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha.
Jensen LH; Renodon-Cornière A; Nitiss KC; Hill BT; Nitiss JL; Jensen PB; Sehested M
Biochem Pharmacol; 2003 Aug; 66(4):623-31. PubMed ID: 12906927
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerases as molecular targets for anticancer drugs.
Buzun K; Bielawska A; Bielawski K; Gornowicz A
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1781-1799. PubMed ID: 32975138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
